Go Pro

Healthcare and Medical Stocks List

This page shows information about the 50 largest healthcare and medical sector stocks including Eli Lilly and Company, Johnson & Johnson, AbbVie and UnitedHealth Group.

Eli Lilly and Company stock logo

1. Eli Lilly and Company NYSE:LLY

$1,208.37 -5.54 (-0.46%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$1,206.69 -1.68 (-0.14%)
As of 09:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. More about Eli Lilly and Company

Pros of Eli Lilly and Company

  • The company recently reported a significant revenue increase, showcasing a year-over-year growth of over 55%, indicating strong market demand for its products.
  • Eli Lilly and Co has a robust net margin of nearly 35%, reflecting efficient operations and profitability, which can lead to higher returns for investors.
  • The current stock price is around $1,042, which is near its 52-week high, suggesting strong investor confidence and potential for further appreciation.

Cons of Eli Lilly and Company

  • The stock has a high price-to-earnings ratio of around 43.56, which may suggest that it is overvalued compared to its earnings, potentially limiting future price appreciation.
  • With a beta of 0.53, the stock is less volatile than the market, which may appeal to conservative investors but could also mean less opportunity for rapid gains.
  • The company has a debt-to-equity ratio of 1.26, indicating a reliance on debt financing, which could pose risks if market conditions change or interest rates rise.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$1.14 trillion
P/E Ratio
42.93
Consensus Rating
Moderate Buy
Consensus Price Target
$1,235.07 (+2.2% Upside)
Volume
3.29 million shares
Average Volume
3.08 million shares
Today's Range
$1,180.30
$1,232.00
50-Day Range
$851.65
$1,226.22
52-Week Range
$623.78
$1,238.00
Dividend Yield
0.57%
Johnson & Johnson stock logo

2. Johnson & Johnson NYSE:JNJ

$262.52 -0.52 (-0.20%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$261.04 -1.48 (-0.56%)
As of 09:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. More about Johnson & Johnson

Pros of Johnson & Johnson

  • The company recently reported a strong quarterly revenue of approximately $24 billion, exceeding analyst expectations, which indicates robust business performance and potential for future growth.
  • Johnson & Johnson has a high return on equity of over 32%, suggesting effective management and a strong ability to generate profits from shareholders' equity.
  • The stock has reached a new 52-week high, reflecting strong investor demand and positive market sentiment, which could indicate a favorable investment opportunity.

Cons of Johnson & Johnson

  • The company faced legal challenges related to its products, which could pose risks to its reputation and financial stability, despite recent favorable outcomes in some lawsuits.
  • Johnson & Johnson's earnings per share for the same quarter last year was higher at $2.77, indicating a potential decline in profitability year-over-year, which may concern investors.
  • The dividend payout ratio is around 62%, which, while sustainable, suggests that a significant portion of earnings is being distributed as dividends, potentially limiting reinvestment in growth opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$631.93 billion
P/E Ratio
30.35
Consensus Rating
Moderate Buy
Consensus Price Target
$256.70 (-2.2% Downside)
Volume
7.95 million shares
Average Volume
8.38 million shares
Today's Range
$254.00
$263.10
50-Day Range
$221.17
$262.52
52-Week Range
$154.21
$263.10
Dividend Yield
2.04%
AbbVie stock logo

3. AbbVie NYSE:ABBV

$260.88 -0.19 (-0.07%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$260.02 -0.86 (-0.33%)
As of 09:22 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. More about AbbVie

Pros of AbbVie

  • AbbVie recently reported earnings per share (EPS) of $2.65, exceeding analysts' expectations, indicating strong financial performance and potential for growth.
  • The company achieved a revenue of $15 billion for the quarter, surpassing estimates, which reflects robust demand for its products and a positive outlook for future sales.
  • AbbVie has a promising pipeline, including the recent FDA approval of Skyrizi for pediatric use, expanding its market reach and potential revenue streams.

Cons of AbbVie

  • AbbVie has a notably high dividend payout ratio of 340.89%, which may raise concerns about sustainability and the ability to maintain dividends in the long term.
  • The company reported a negative return on equity of 576.45%, indicating potential inefficiencies in generating profit from shareholders' equity.
  • Despite recent successes, AbbVie faces significant competition in the biopharmaceutical market, which could impact its market share and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$460.92 billion
P/E Ratio
128.51
Consensus Rating
Moderate Buy
Consensus Price Target
$255.00 (-2.3% Downside)
Volume
7.10 million shares
Average Volume
8.34 million shares
Today's Range
$250.51
$261.64
50-Day Range
$197.24
$260.88
52-Week Range
$184.63
$261.64
Dividend Yield
2.65%
UnitedHealth Group stock logo

4. UnitedHealth Group NYSE:UNH

$424.64 -0.72 (-0.17%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$424.08 -0.56 (-0.13%)
As of 09:24 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. More about UnitedHealth Group

Pros of UnitedHealth Group

  • The company reported a quarterly earnings per share of $7.23, exceeding analyst expectations, which indicates strong financial performance and potential for growth.
  • UnitedHealth Group has increased its quarterly dividend to $2.32 per share, reflecting a commitment to returning value to shareholders, with an annualized dividend yield of approximately 2.2%.
  • Analysts forecast earnings per share of $18.32 for the current year, suggesting positive growth prospects and confidence in the company's future performance.

Cons of UnitedHealth Group

  • The company's net margin is relatively low at 2.68%, which may raise concerns about profitability and cost management in a competitive healthcare market.
  • UnitedHealth Group's payout ratio is currently at 70.09%, indicating that a significant portion of earnings is being distributed as dividends, which could limit reinvestment in growth opportunities.
  • Despite recent positive performance, the healthcare sector can be volatile and subject to regulatory changes, which may impact future earnings and stock performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$385.63 billion
P/E Ratio
32.07
Consensus Rating
Moderate Buy
Consensus Price Target
$411.42 (-3.1% Downside)
Volume
3.92 million shares
Average Volume
5.97 million shares
Today's Range
$420.54
$430.20
50-Day Range
$354.64
$427.47
52-Week Range
$234.60
$430.20
Dividend Yield
2.18%
Merck & Co., Inc. stock logo

5. Merck & Co., Inc. NYSE:MRK

$129.34 -0.22 (-0.17%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$129.92 +0.59 (+0.45%)
As of 09:24 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. More about Merck & Co., Inc.

Pros of Merck & Co., Inc.

  • Merck has demonstrated strong financial performance with a return on equity of over 27%, indicating effective management and profitability.
  • The company recently reported a year-over-year revenue increase of nearly 5%, showcasing its ability to grow even in competitive markets.
  • Merck's earnings per share (EPS) guidance for the current fiscal year is projected at around $5.17, reflecting positive expectations from analysts.

Cons of Merck & Co., Inc.

  • The company's dividend payout ratio is quite high at nearly 96%, which may raise concerns about sustainability and future dividend increases.
  • Merck operates in a highly competitive biopharmaceutical industry, which can lead to pressure on pricing and profit margins.
  • Recent developments in the market may pose risks, as new entrants and innovations could impact Merck's market share.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$319.44 billion
P/E Ratio
36.43
Consensus Rating
Moderate Buy
Consensus Price Target
$131.83 (+1.9% Upside)
Volume
7.82 million shares
Average Volume
11.34 million shares
Today's Range
$125.99
$129.61
50-Day Range
$109.33
$129.34
52-Week Range
$76.66
$130.29
Dividend Yield
2.62%
Novartis stock logo

6. Novartis NYSE:NVS

$159.82 -0.08 (-0.05%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$157.34 -2.47 (-1.55%)
As of 09:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More about Novartis

Pros of Novartis

  • Novartis AG is actively engaged in the development of innovative therapies, including inclisiran, which targets LDL cholesterol reduction, showcasing its commitment to addressing significant health issues.
  • The current stock price is around $126.40, reflecting a positive performance trend over the past year, which may indicate investor confidence in the company's future prospects.
  • With a strong focus on various therapeutic areas such as oncology and immunology, Novartis AG is well-positioned to capitalize on growing healthcare demands and market opportunities.

Cons of Novartis

  • The short percentage of float is relatively low, indicating that there may not be significant bearish sentiment among investors, which could limit potential upside in the stock price.
  • Despite recent positive performance, the pharmaceutical industry is highly competitive, and Novartis AG faces challenges from other companies developing similar therapies.
  • Institutional ownership is at 7.05%, which may suggest limited confidence from larger investors, potentially impacting stock stability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$304.96 billion
P/E Ratio
22.90
Consensus Rating
Hold
Consensus Price Target
$141.20 (-11.7% Downside)
Volume
1.59 million shares
Average Volume
2.12 million shares
Today's Range
$157.00
$160.57
50-Day Range
$142.99
$159.82
52-Week Range
$112.34
$170.46
Dividend Yield
1.93%
Novo Nordisk A/S stock logo

7. Novo Nordisk A/S NYSE:NVO

$50.39 -0.04 (-0.09%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$49.40 -0.98 (-1.95%)
As of 09:24 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More about Novo Nordisk A/S

Pros of Novo Nordisk A/S

  • The current stock price is around $43.90, which may present a buying opportunity for investors looking for growth in the pharmaceutical sector.
  • With a strong return on equity of over 63%, Novo Nordisk demonstrates effective management and profitability, indicating potential for continued financial success.
  • The company reported a net margin of 37.23%, showcasing its ability to convert revenue into profit efficiently, which is attractive for investors seeking solid returns.

Cons of Novo Nordisk A/S

  • Despite a strong market position, the stock has faced downgrades from some analysts, which may signal potential volatility and uncertainty in the stock's future performance.
  • The price-to-earnings ratio is around 10.77, which, while not excessively high, may indicate that the stock is fairly valued, limiting upside potential for aggressive investors.
  • With a debt-to-equity ratio of 0.59, while manageable, it suggests that the company is not entirely debt-free, which could pose risks in a rising interest rate environment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$224.97 billion
P/E Ratio
11.83
Consensus Rating
Hold
Consensus Price Target
$65.56 (+30.1% Upside)
Volume
12.06 million shares
Average Volume
11.97 million shares
Today's Range
$49.78
$50.90
50-Day Range
$38.54
$50.39
52-Week Range
$35.12
$71.79
Dividend Yield
3.46%
Amgen stock logo

8. Amgen NASDAQ:AMGN

$374.15 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$372.52 -1.63 (-0.44%)
As of 09:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. More about Amgen

Pros of Amgen

  • Amgen Inc. has a strong earnings forecast, with analysts expecting an EPS of approximately 22.38 for the current year, indicating solid profitability potential.
  • The current stock price is around $323, which may present a buying opportunity for investors looking for value in the biotechnology sector.
  • Recent upgrades from major financial institutions, including a "buy" rating from UBS Group with a target price of $400, suggest positive market sentiment and potential for price appreciation.

Cons of Amgen

  • Recent insider selling, including a significant transaction by a senior vice president, may raise concerns about the company's short-term outlook and internal confidence.
  • With a consensus rating of "Hold" from analysts, there may be limited upside potential compared to other investment opportunities in the market.
  • Some analysts have lowered their price targets, indicating a cautious approach towards Amgen Inc.'s future performance amidst market volatility.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$201.93 billion
P/E Ratio
26.04
Consensus Rating
Hold
Consensus Price Target
$355.50 (-5.0% Downside)
Volume
2.48 million shares
Average Volume
2.92 million shares
Today's Range
$363.39
$375.15
50-Day Range
$324.39
$374.15
52-Week Range
$269.77
$391.29
Dividend Yield
2.69%
Thermo Fisher Scientific stock logo

9. Thermo Fisher Scientific NYSE:TMO

$522.38 -1.06 (-0.20%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$522.02 -0.37 (-0.07%)
As of 09:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. More about Thermo Fisher Scientific

Pros of Thermo Fisher Scientific

  • The current stock price is around $643, reflecting strong market performance and investor confidence in the company's growth potential.
  • Thermo Fisher Scientific Inc. reported a significant increase in quarterly revenue, demonstrating a year-over-year growth of 6.2%, which indicates robust demand for its products and services.
  • The company has a solid return on equity of 16.86%, suggesting effective management and a strong ability to generate profits from shareholders' investments.

Cons of Thermo Fisher Scientific

  • The price-to-earnings ratio of 27.77 may suggest that the stock is overvalued compared to its earnings, which could deter value-focused investors.
  • The price-to-earnings-growth ratio of 2.27 indicates that the stock's price may be high relative to its expected earnings growth, which could limit upside potential.
  • With a beta of 0.88, the stock is less volatile than the market, which may not appeal to investors seeking high-risk, high-reward opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$194.13 billion
P/E Ratio
28.72
Consensus Rating
Moderate Buy
Consensus Price Target
$605.09 (+15.8% Upside)
Volume
2.32 million shares
Average Volume
2.09 million shares
Today's Range
$511.98
$529.15
50-Day Range
$438.16
$522.38
52-Week Range
$403.36
$643.99
Dividend Yield
0.36%
Abbott Laboratories stock logo

10. Abbott Laboratories NYSE:ABT

$95.25 -0.15 (-0.16%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$95.03 -0.22 (-0.23%)
As of 09:24 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More about Abbott Laboratories

Pros of Abbott Laboratories

  • The company has demonstrated strong revenue growth, with a year-over-year increase of 7.8%, indicating robust business performance.
  • Abbott Laboratories has set an earnings per share (EPS) guidance for FY 2026 between 5.380 and 5.580, suggesting positive future profitability expectations.
  • The current stock price is around $118.30, which reflects a moderate buy rating from analysts, indicating potential for appreciation.

Cons of Abbott Laboratories

  • Some analysts have recently lowered their target prices for Abbott Laboratories, indicating a cautious outlook on the stock's short-term performance.
  • The company's dividend payout ratio is currently at 70.59%, which may raise concerns about sustainability, especially if earnings do not grow as expected.
  • Despite positive growth, the stock has faced price adjustments from various analysts, which could signal volatility and uncertainty in the market.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$165.91 billion
P/E Ratio
26.68
Consensus Rating
Moderate Buy
Consensus Price Target
$118.42 (+24.3% Upside)
Volume
10.63 million shares
Average Volume
13.09 million shares
Today's Range
$91.91
$95.74
50-Day Range
$82.58
$95.25
52-Week Range
$81.97
$137.49
Dividend Yield
2.64%
Gilead Sciences stock logo

11. Gilead Sciences NASDAQ:GILD

$131.27 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$132.48 +1.20 (+0.92%)
As of 09:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More about Gilead Sciences

Pros of Gilead Sciences

  • The company recently reported earnings per share of $2.03, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
  • Gilead Sciences, Inc. has a solid market capitalization of approximately $155.43 billion, suggesting it is a well-established player in the biopharmaceutical industry.
  • The firm has a healthy return on equity of 48.19%, reflecting effective management and the ability to generate profits from shareholders' equity.

Cons of Gilead Sciences

  • The company has set its fiscal year 2026 guidance at a range of -1.050 to -0.650 EPS, indicating potential challenges ahead in maintaining profitability.
  • Analysts predict a negative earnings per share of -0.8 for the current fiscal year, which could signal underlying issues affecting the company's financial health.
  • Gilead Sciences, Inc. has a debt-to-equity ratio of 0.89, which, while manageable, suggests that the company is utilizing a significant amount of debt to finance its operations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$162.98 billion
P/E Ratio
17.88
Consensus Rating
Moderate Buy
Consensus Price Target
$159.22 (+21.3% Upside)
Volume
7.87 million shares
Average Volume
8.04 million shares
Today's Range
$126.46
$131.58
50-Day Range
$121.48
$136.30
52-Week Range
$107.75
$157.29
Dividend Yield
2.50%
Intuitive Surgical stock logo

12. Intuitive Surgical NASDAQ:ISRG

$426.01 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$426.25 +0.24 (+0.06%)
As of 09:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. More about Intuitive Surgical

Pros of Intuitive Surgical

  • The company reported strong earnings per share of $2.50 for the latest quarter, significantly exceeding analyst expectations, which indicates robust financial performance.
  • Intuitive Surgical, Inc. has shown impressive revenue growth, with a 23% increase compared to the same quarter last year, suggesting a strong demand for its products.
  • The current stock price is around $420, reflecting a solid position in the market and potential for future appreciation as the company continues to innovate.

Cons of Intuitive Surgical

  • Recent insider selling, including significant transactions by senior executives, may raise concerns about the company's future prospects and could indicate a lack of confidence among insiders.
  • Some analysts have lowered their price targets for the stock, which could suggest a more cautious outlook on the company's growth potential in the near term.
  • The stock has experienced fluctuations, and while it has shown growth, market volatility could pose risks for investors looking for stability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$150.88 billion
P/E Ratio
51.64
Consensus Rating
Moderate Buy
Consensus Price Target
$573.42 (+34.6% Upside)
Volume
3.14 million shares
Average Volume
2.27 million shares
Today's Range
$406.47
$426.02
50-Day Range
$397.68
$482.22
52-Week Range
$396.68
$603.88
Dividend Yield
N/A
Danaher stock logo

13. Danaher NYSE:DHR

$197.85 -0.08 (-0.04%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$197.58 -0.27 (-0.14%)
As of 09:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. More about Danaher

Pros of Danaher

  • The current stock price is around $188, which reflects a strong market position and potential for growth.
  • Danaher Co. has demonstrated solid financial health with a quick ratio of 1.52 and a current ratio of 1.87, indicating good short-term liquidity and ability to cover liabilities.
  • The company reported a net margin of 14.89%, showcasing effective cost management and profitability.

Cons of Danaher

  • The company has a price-to-earnings (P/E) ratio of 34.81, which may indicate that the stock is overvalued compared to its earnings.
  • Recent revenue of $5.95 billion fell short of analysts' expectations of $6 billion, which could raise concerns about future growth potential.
  • Danaher Co. has a beta of 0.81, suggesting lower volatility compared to the market, which may not appeal to investors seeking high-risk, high-reward opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$140.03 billion
P/E Ratio
38.27
Consensus Rating
Moderate Buy
Consensus Price Target
$233.61 (+18.1% Upside)
Volume
3.99 million shares
Average Volume
3.84 million shares
Today's Range
$194.47
$198.23
50-Day Range
$161.95
$197.85
52-Week Range
$160.93
$242.80
Dividend Yield
0.81%
Pfizer stock logo

14. Pfizer NYSE:PFE

$24.29 -0.03 (-0.12%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$24.16 -0.13 (-0.52%)
As of 09:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. More about Pfizer

Pros of Pfizer

  • The current stock price is around $28, reflecting a stable position in the market.
  • Pfizer Inc. reported a quarterly earnings per share (EPS) of $0.75, exceeding analyst expectations, which indicates strong financial performance.
  • The company has a solid revenue growth of 5.4% year-over-year, showcasing its ability to increase sales and market presence.

Cons of Pfizer

  • The company has a high dividend payout ratio of 131.30%, which may raise concerns about sustainability in future earnings.
  • Pfizer Inc. has a relatively low net margin of 11.83%, suggesting that profitability could be a concern compared to competitors.
  • The stock has a beta of 0.34, indicating lower volatility, which may not appeal to investors seeking high-risk, high-reward opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$138.45 billion
P/E Ratio
18.54
Consensus Rating
Hold
Consensus Price Target
$28.59 (+17.7% Upside)
Volume
52.80 million shares
Average Volume
46.88 million shares
Today's Range
$24.13
$24.57
50-Day Range
$23.64
$27.01
52-Week Range
$23.11
$28.75
Dividend Yield
7.07%
Vertex Pharmaceuticals stock logo

15. Vertex Pharmaceuticals NASDAQ:VRTX

$528.04 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$524.98 -3.06 (-0.58%)
As of 09:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More about Vertex Pharmaceuticals

Pros of Vertex Pharmaceuticals

  • The current stock price is around $440, which is significantly below its 12-month high, indicating potential for growth.
  • Vertex Pharmaceuticals Incorporated reported a strong quarterly earnings per share of $4.47, surpassing analysts' expectations, which reflects robust financial performance.
  • The company has a high net margin of over 35%, suggesting efficient management and profitability, which can be attractive to investors looking for solid returns.

Cons of Vertex Pharmaceuticals

  • Insider selling has been notable, with executives selling shares under pre-arranged trading plans, which may signal a lack of confidence in the stock's future performance.
  • The price-to-earnings (PE) ratio of 28.19 suggests that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • With a beta of 0.30, the stock is less volatile than the market, which may limit potential gains during bullish market conditions.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$134.02 billion
P/E Ratio
31.32
Consensus Rating
Moderate Buy
Consensus Price Target
$555.91 (+5.3% Upside)
Volume
1.84 million shares
Average Volume
1.74 million shares
Today's Range
$501.53
$529.14
50-Day Range
$423.24
$528.04
52-Week Range
$362.50
$529.14
Dividend Yield
N/A
CVS Health stock logo

16. CVS Health NYSE:CVS

$104.74 +0.02 (+0.02%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$104.40 -0.33 (-0.32%)
As of 09:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. More about CVS Health

Pros of CVS Health

  • The current stock price is around $91, which is significantly lower than its 12-month high of $106.15, indicating potential for price appreciation.
  • CVS Health Co. reported a strong quarterly earnings performance, with earnings per share (EPS) of $2.57, surpassing analysts' expectations, which reflects robust operational efficiency.
  • The company has shown a year-over-year revenue growth of 6.2%, indicating a positive trend in sales and demand for its services.

Cons of CVS Health

  • The company has a relatively low quick ratio of 0.66, which may indicate potential liquidity issues in meeting short-term obligations.
  • CVS Health Co. has a high P/E ratio of 45.98, suggesting that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • The net margin of 0.72% is quite slim, indicating that the company retains a small portion of revenue as profit, which may raise concerns about overall profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$133.64 billion
P/E Ratio
46.14
Consensus Rating
Moderate Buy
Consensus Price Target
$101.28 (-3.3% Downside)
Volume
5.52 million shares
Average Volume
7.66 million shares
Today's Range
$103.22
$105.23
50-Day Range
$77.92
$104.83
52-Week Range
$58.50
$106.15
Dividend Yield
2.54%
Stryker stock logo

17. Stryker NYSE:SYK

$326.41 -0.13 (-0.04%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$327.50 +1.09 (+0.33%)
As of 09:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. More about Stryker

Pros of Stryker

  • The company has set its FY 2026 earnings per share (EPS) guidance between 14.900 and 15.100, indicating strong growth potential.
  • Recent quarterly revenue showed an increase of 2.6% compared to the same period last year, suggesting a positive trend in sales performance.
  • The current stock price is around $306, which may present a buying opportunity for investors looking for growth in the medical technology sector.

Cons of Stryker

  • Insider selling has been significant, with a total of 323,264 shares sold recently, which may indicate a lack of confidence among executives in the company's short-term performance.
  • The stock is currently owned 4.60% by insiders, which may suggest limited insider confidence in the company's future growth prospects.
  • Despite the revenue growth, the overall market conditions in the medical technology sector can be volatile, which may impact Stryker Co.'s performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$125.13 billion
P/E Ratio
37.78
Consensus Rating
Moderate Buy
Consensus Price Target
$395.33 (+21.1% Upside)
Volume
2.61 million shares
Average Volume
2.43 million shares
Today's Range
$307.49
$327.76
50-Day Range
$282.85
$332.31
52-Week Range
$281.00
$404.87
Dividend Yield
1.08%
Bristol Myers Squibb stock logo

18. Bristol Myers Squibb NYSE:BMY

$58.05 -0.08 (-0.14%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$57.89 -0.16 (-0.28%)
As of 09:19 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More about Bristol Myers Squibb

Pros of Bristol Myers Squibb

  • The company reported a quarterly revenue of approximately $11.49 billion, exceeding analyst expectations, indicating strong financial performance.
  • Bristol-Myers Squibb has a high return on equity of about 64.87%, suggesting effective management and profitability in generating returns for shareholders.
  • The current stock price is around $61.67, which is near its 12-month high of $62.89, reflecting positive market sentiment.

Cons of Bristol Myers Squibb

  • The company's net margin is around 15.01%, which, while positive, may indicate tighter profit margins compared to competitors in the biopharmaceutical sector.
  • Insider ownership is relatively low at 0.05%, which may raise concerns about alignment between management and shareholder interests.
  • Recent insider selling, including a significant transaction by an executive vice president, could signal potential concerns about the company's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$118.54 billion
P/E Ratio
16.31
Consensus Rating
Hold
Consensus Price Target
$61.31 (+5.6% Upside)
Volume
9.99 million shares
Average Volume
12.39 million shares
Today's Range
$56.41
$58.14
50-Day Range
$54.10
$60.75
52-Week Range
$42.52
$62.89
Dividend Yield
4.34%
GSK stock logo

19. GSK NYSE:GSK

$53.69 +0.03 (+0.05%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$53.83 +0.14 (+0.27%)
As of 09:20 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More about GSK

Pros of GSK

  • The current stock price is around $43.16, which may present a buying opportunity for investors looking for value.
  • GSK plc has shown a positive fifty-two week performance, indicating potential growth and investor confidence.
  • Institutional ownership is relatively high, suggesting that large investors have confidence in GSK plc's future prospects.

Cons of GSK

  • Recent performance has shown a decline in the fifty-two week performance, which may raise concerns about the company's growth trajectory.
  • The average daily volume has decreased, indicating reduced trading activity and potentially lower liquidity for investors.
  • There has been a notable decrease in shares shorted compared to the previous month, which could suggest a lack of confidence among some investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$108.72 billion
P/E Ratio
13.95
Consensus Rating
Hold
Consensus Price Target
$53.00 (-1.3% Downside)
Volume
3.80 million shares
Average Volume
3.69 million shares
Today's Range
$52.25
$53.84
50-Day Range
$49.06
$55.61
52-Week Range
$35.45
$61.69
Dividend Yield
3.38%
Medtronic stock logo

20. Medtronic NYSE:MDT

$83.07 -0.12 (-0.15%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$82.88 -0.19 (-0.22%)
As of 09:24 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. More about Medtronic

Pros of Medtronic

  • The company recently reported earnings per share (EPS) of $1.55, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
  • Medtronic plc has demonstrated a solid revenue increase of nearly 10% year-over-year, reflecting its ability to expand its market presence and product offerings.
  • The current stock price is around $85, which may present a favorable entry point for investors looking to capitalize on the company's growth trajectory.

Cons of Medtronic

  • The net margin of 13.20% may suggest that while the company is profitable, there could be concerns about cost management and overall profitability compared to industry peers.
  • Medtronic plc's EPS has decreased from $1.62 in the same quarter last year, which could indicate challenges in maintaining growth momentum.
  • With a payout ratio of 76.14%, there may be concerns about the sustainability of dividend payments, especially if earnings do not continue to grow.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$106.33 billion
P/E Ratio
22.27
Consensus Rating
Moderate Buy
Consensus Price Target
$99.00 (+19.2% Upside)
Volume
9.68 million shares
Average Volume
8.86 million shares
Today's Range
$79.90
$83.31
50-Day Range
$73.72
$83.80
52-Week Range
$73.31
$106.33
Dividend Yield
3.46%
Sanofi stock logo

21. Sanofi NASDAQ:SNY

$43.16 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$43.42 +0.26 (+0.60%)
As of 09:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More about Sanofi

Pros of Sanofi

  • The current stock price is around $43.60, which is near its one-year low, potentially offering a buying opportunity for value investors.
  • Sanofi has a strong market capitalization of approximately $108.66 billion, indicating a solid position in the pharmaceutical industry.
  • The company maintains a low debt-to-equity ratio of 0.20, suggesting financial stability and lower risk associated with debt obligations.

Cons of Sanofi

  • Despite a strong market presence, the stock has received a mix of ratings, with several analysts maintaining a "neutral" stance, indicating uncertainty about future performance.
  • The company's quick ratio of 0.73 suggests potential liquidity issues, meaning it may struggle to meet short-term obligations without selling inventory.
  • Sanofi's P/E ratio of 12.38, while not excessively high, may indicate that the stock is fairly valued, limiting upside potential for aggressive growth investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$104.64 billion
P/E Ratio
12.06
Consensus Rating
Hold
Consensus Price Target
$51.00 (+18.2% Upside)
Volume
3.46 million shares
Average Volume
3.95 million shares
Today's Range
$42.38
$43.41
50-Day Range
$41.33
$47.53
52-Week Range
$40.89
$52.68
Dividend Yield
4.09%
McKesson stock logo

22. McKesson NYSE:MCK

$786.18 -0.13 (-0.02%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$783.18 -3.00 (-0.38%)
As of 09:20 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. More about McKesson

Pros of McKesson

  • The current stock price is around $768, reflecting a stable market position and potential for growth.
  • McKesson Co. recently reported earnings per share of $11.69, exceeding analyst expectations, indicating strong financial performance.
  • The company has shown a year-over-year revenue increase of 6.0%, suggesting a positive growth trajectory.

Cons of McKesson

  • The company has a negative return on equity of 345.35%, which may raise concerns about its efficiency in generating profits from shareholders' equity.
  • Recent revenue figures fell short of analyst estimates, which could indicate challenges in meeting market expectations.
  • Insider selling activity has been notable, with executives reducing their holdings, which might suggest a lack of confidence in the company's short-term prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$92.05 billion
P/E Ratio
20.44
Consensus Rating
Moderate Buy
Consensus Price Target
$960.53 (+22.2% Upside)
Volume
879,432 shares
Average Volume
1.06 million shares
Today's Range
$770.00
$787.36
50-Day Range
$724.87
$835.97
52-Week Range
$637.00
$999.00
Dividend Yield
0.42%
HCA Healthcare stock logo

23. HCA Healthcare NYSE:HCA

$409.99 -0.51 (-0.12%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$410.72 +0.73 (+0.18%)
As of 09:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. More about HCA Healthcare

Pros of HCA Healthcare

  • The current stock price is around $412, which is significantly lower than its 52-week high of $556.52, potentially offering a buying opportunity for investors looking for value.
  • HCA Healthcare, Inc. has shown a revenue increase of 4.3% compared to the same quarter last year, indicating growth and resilience in its business operations.
  • The company has a solid dividend yield of 0.8%, providing a steady income stream for investors, with a recent quarterly dividend of $0.78 per share.

Cons of HCA Healthcare

  • The company has a negative return on equity of 295.93%, which may raise concerns about its profitability and efficiency in generating returns for shareholders.
  • Despite revenue growth, the company reported an EPS of $7.15, which missed analysts' consensus estimates, indicating potential challenges in meeting market expectations.
  • HCA Healthcare, Inc. operates in a highly competitive and regulated industry, which can pose risks to its market position and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$90.95 billion
P/E Ratio
14.10
Consensus Rating
Moderate Buy
Consensus Price Target
$503.00 (+22.7% Upside)
Volume
1.62 million shares
Average Volume
1.44 million shares
Today's Range
$395.10
$416.54
50-Day Range
$360.99
$474.34
52-Week Range
$330.00
$556.52
Dividend Yield
0.76%
Elevance Health stock logo

24. Elevance Health NYSE:ELV

$416.97 -0.92 (-0.22%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$417.14 +0.17 (+0.04%)
As of 09:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Market Capitalization
$90.55 billion
P/E Ratio
17.74
Consensus Rating
Moderate Buy
Consensus Price Target
$419.16 (+0.5% Upside)
Volume
1.60 million shares
Average Volume
1.64 million shares
Today's Range
$414.68
$427.19
50-Day Range
$344.64
$424.16
52-Week Range
$273.71
$427.19
Dividend Yield
1.65%
Cigna Group stock logo

25. Cigna Group NYSE:CI

$287.50 -0.27 (-0.10%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$286.50 -0.99 (-0.35%)
As of 09:20 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. More about Cigna Group

Pros of Cigna Group

  • The current stock price is around $338.30, reflecting a consensus target price that suggests potential for growth.
  • The Cigna Group has a solid dividend yield of 2.2%, which can provide a steady income stream for investors.
  • With a dividend payout ratio of 26.45%, the company demonstrates a commitment to returning value to shareholders while maintaining sufficient reinvestment in the business.

Cons of Cigna Group

  • Some analysts have recently downgraded their price targets for The Cigna Group, which may indicate concerns about future performance.
  • The competitive landscape in the healthcare sector is intense, which could pressure profit margins and growth potential.
  • Market volatility can impact stock performance, and recent economic uncertainties may pose risks to The Cigna Group's financial stability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$76.05 billion
P/E Ratio
12.19
Consensus Rating
Moderate Buy
Consensus Price Target
$338.30 (+17.7% Upside)
Volume
2.10 million shares
Average Volume
1.51 million shares
Today's Range
$278.79
$287.77
50-Day Range
$271.03
$300.36
52-Week Range
$239.51
$323.10
Dividend Yield
2.17%
Regeneron Pharmaceuticals stock logo

26. Regeneron Pharmaceuticals NASDAQ:REGN

$654.27 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$652.88 -1.39 (-0.21%)
As of 09:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More about Regeneron Pharmaceuticals

Pros of Regeneron Pharmaceuticals

  • The company reported a significant earnings per share (EPS) of $9.47 for the latest quarter, surpassing analyst expectations, which indicates strong financial performance and potential for future growth.
  • Regeneron Pharmaceuticals, Inc. achieved a revenue of $3.61 billion during the quarter, reflecting a year-over-year increase of 19.0%, showcasing its ability to grow sales effectively.
  • The current stock price is around $720, which may present an attractive entry point for investors looking to capitalize on the company's growth trajectory.

Cons of Regeneron Pharmaceuticals

  • Despite strong earnings, the stock's dividend yield is relatively low at 0.6%, which may not attract income-focused investors looking for higher returns from dividends.
  • The company faces intense competition in the biopharmaceutical sector, which could impact its market share and pricing power over time.
  • Regeneron Pharmaceuticals, Inc. relies heavily on its proprietary drug discovery technologies, and any setbacks in research and development could adversely affect its future product pipeline.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$69.17 billion
P/E Ratio
15.94
Consensus Rating
Moderate Buy
Consensus Price Target
$790.48 (+20.8% Upside)
Volume
1.07 million shares
Average Volume
1.00 million shares
Today's Range
$625.70
$654.94
50-Day Range
$600.66
$766.02
52-Week Range
$532.60
$821.11
Dividend Yield
0.57%
Boston Scientific stock logo

27. Boston Scientific NYSE:BSX

$45.09 -0.05 (-0.12%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$45.14 +0.05 (+0.11%)
As of 09:21 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More about Boston Scientific

Pros of Boston Scientific

  • The company has demonstrated strong financial performance, with a recent return on equity of over 19%, indicating effective management and profitability.
  • Boston Scientific Co. reported a significant revenue increase of approximately 11.6% year-over-year, showcasing its growth potential in the medical device market.
  • With a net margin of around 17%, the company is effectively managing its costs, which can lead to higher profitability for shareholders.

Cons of Boston Scientific

  • Despite recent growth, the company faces intense competition in the medical device industry, which could impact its market share and profitability.
  • Analysts predict earnings per share of 3.36 for the current fiscal year, which may not meet investor expectations if growth slows.
  • Market volatility can affect stock performance, and any downturn in the broader market could negatively impact Boston Scientific Co.'s stock price.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$67.01 billion
P/E Ratio
18.86
Consensus Rating
Moderate Buy
Consensus Price Target
$83.36 (+84.9% Upside)
Volume
26.34 million shares
Average Volume
19.70 million shares
Today's Range
$43.45
$45.80
50-Day Range
$42.64
$65.89
52-Week Range
$42.25
$109.50
Dividend Yield
N/A
argenex stock logo

28. argenex NASDAQ:ARGX

$939.68 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$939.00 -0.68 (-0.07%)
As of 09:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. More about argenex

Pros of argenex

  • The current stock price is around $799, indicating a strong market position and potential for growth.
  • Recent short interest data shows a decrease in shares shorted, suggesting that investor sentiment may be improving.
  • With an average daily volume of approximately 345,000 shares, there is significant trading activity, which can indicate liquidity and investor interest.

Cons of argenex

  • The company has a relatively high short percentage of float, which may indicate that some investors are betting against the stock.
  • There has been no significant institutional ownership, which can sometimes reflect a lack of confidence from larger investors.
  • Recent performance metrics show no change in the fifty-two week performance, suggesting stagnation in growth.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$58.44 billion
P/E Ratio
41.84
Consensus Rating
Moderate Buy
Consensus Price Target
$1,034.56 (+10.1% Upside)
Volume
381,153 shares
Average Volume
365,485 shares
Today's Range
$921.15
$953.58
50-Day Range
$775.03
$939.68
52-Week Range
$536.02
$953.58
Dividend Yield
N/A
Cencora stock logo

29. Cencora NYSE:COR

$296.43 -0.08 (-0.03%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$296.65 +0.22 (+0.07%)
As of 09:17 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. More about Cencora

Pros of Cencora

  • The company has recently announced a share buyback plan allowing for the repurchase of $2.00 billion in shares, indicating management's belief that the stock is undervalued.
  • Cencora, Inc. reported a revenue increase of 3.9% compared to the same quarter last year, showcasing its growth potential in the healthcare services sector.
  • The current stock price is around $350, which reflects a favorable valuation compared to its historical performance and analyst price targets.

Cons of Cencora

  • The company reported earnings per share of $4.75, which missed analysts' expectations, indicating potential challenges in meeting growth targets.
  • Cencora's net margin is relatively low at 0.78%, which may raise concerns about profitability and operational efficiency.
  • Despite revenue growth, the company’s revenue of $78.36 billion fell short of consensus estimates, suggesting possible market pressures or operational hurdles.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$57.67 billion
P/E Ratio
22.73
Consensus Rating
Moderate Buy
Consensus Price Target
$367.75 (+24.1% Upside)
Volume
1.46 million shares
Average Volume
1.41 million shares
Today's Range
$288.80
$296.83
50-Day Range
$253.20
$312.09
52-Week Range
$244.82
$377.54
Dividend Yield
0.81%
Cardinal Health stock logo

30. Cardinal Health NYSE:CAH

$238.79 -0.15 (-0.06%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$237.71 -1.08 (-0.45%)
As of 09:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. More about Cardinal Health

Pros of Cardinal Health

  • The company recently reported earnings per share (EPS) of $3.17, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
  • Cardinal Health, Inc. has a consensus rating of "Moderate Buy" from analysts, suggesting positive sentiment and confidence in the company's future performance.
  • The current stock price is around $246.93, which reflects a favorable valuation compared to its projected earnings growth.

Cons of Cardinal Health

  • The company has a negative return on equity of 92.61%, which may raise concerns about its efficiency in generating profits from shareholders' equity.
  • Despite revenue growth, Cardinal Health, Inc. reported a net margin of only 0.62%, indicating that profitability may be a challenge.
  • Some analysts have set lower price targets for the stock, with estimates as low as $215.00, suggesting potential volatility and uncertainty in the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$55.93 billion
P/E Ratio
36.51
Consensus Rating
Moderate Buy
Consensus Price Target
$247.80 (+3.8% Upside)
Volume
2.04 million shares
Average Volume
2.28 million shares
Today's Range
$237.53
$240.91
50-Day Range
$182.62
$238.79
52-Week Range
$137.75
$240.93
Dividend Yield
0.86%
Edwards Lifesciences stock logo

31. Edwards Lifesciences NYSE:EW

$94.31 -0.06 (-0.06%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$93.92 -0.39 (-0.42%)
As of 08:57 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. More about Edwards Lifesciences

Pros of Edwards Lifesciences

  • The company reported earnings per share of $0.78, exceeding analysts' expectations, indicating strong financial performance and potential for growth.
  • With a revenue of $1.65 billion for the recent quarter, which is a 16.7% increase year-over-year, Edwards Lifesciences Co. demonstrates robust sales growth, suggesting a solid market position.
  • Analysts have a consensus rating of "Moderate Buy" for the stock, with a target price around $96.39, indicating positive sentiment and potential for price appreciation.

Cons of Edwards Lifesciences

  • Despite strong earnings, the stock price has shown volatility, which can be a concern for risk-averse investors looking for stability.
  • Insider selling activity has been noted, with significant shares sold recently, which may raise concerns about the confidence of executives in the company's future performance.
  • The company operates in a highly competitive medical technology sector, which can pose risks to maintaining market share and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$54.31 billion
P/E Ratio
50.17
Consensus Rating
Moderate Buy
Consensus Price Target
$96.39 (+2.2% Upside)
Volume
3.19 million shares
Average Volume
4.34 million shares
Today's Range
$91.82
$94.47
50-Day Range
$77.11
$94.31
52-Week Range
$72.30
$94.47
Dividend Yield
N/A
Takeda Pharmaceutical stock logo

32. Takeda Pharmaceutical NYSE:TAK

$16.74 -0.04 (-0.21%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$16.95 +0.22 (+1.28%)
As of 09:21 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More about Takeda Pharmaceutical

Pros of Takeda Pharmaceutical

  • The current stock price is around $13.73, which may present a buying opportunity for investors looking for value in the pharmaceutical sector.
  • Takeda Pharmaceutical Company Limited has a diverse portfolio of products across various therapeutic areas, including oncology and immunology, which can help mitigate risks associated with reliance on a single product.
  • Recent collaborations and licensing agreements with notable companies and research institutions enhance Takeda's innovation potential and may lead to the development of new therapies.

Cons of Takeda Pharmaceutical

  • Despite recent positive developments, the company's institutional ownership percentage is relatively low, which may indicate a lack of confidence from larger investors.
  • The short percentage of float is low, suggesting that there may not be significant investor interest in betting against the stock, which could limit potential price movements.
  • Takeda's performance over the past year has been modest, with a 52-week performance increase of only about 5%, which may not meet the expectations of growth-oriented investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$53.26 billion
P/E Ratio
42.91
Consensus Rating
Hold
Consensus Price Target
N/A
Volume
3.51 million shares
Average Volume
2.64 million shares
Today's Range
$16.42
$16.77
50-Day Range
$15.02
$16.74
52-Week Range
$12.99
$18.90
Dividend Yield
2.87%
Humana stock logo

33. Humana NYSE:HUM

$396.38 -0.37 (-0.09%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$395.00 -1.38 (-0.35%)
As of 09:22 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. More about Humana

Pros of Humana

  • The current stock price is around $263.86, which is significantly lower than its 52-week high, indicating potential for growth.
  • Humana Inc. reported a strong earnings per share (EPS) of $10.31, exceeding analyst expectations, which reflects robust financial performance.
  • The company has a solid market capitalization of $44.34 billion, suggesting stability and a strong position in the health insurance sector.

Cons of Humana

  • The P/E ratio of 39.50 indicates that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • Humana Inc. has a net margin of only 0.82%, suggesting that the company retains a small portion of revenue as profit, which may raise concerns about profitability.
  • Recent analyst ratings show mixed sentiments, with several firms downgrading their price targets, indicating uncertainty in future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$47.59 billion
P/E Ratio
42.39
Consensus Rating
Hold
Consensus Price Target
$293.09 (-26.1% Downside)
Volume
1.40 million shares
Average Volume
1.39 million shares
Today's Range
$391.64
$415.00
50-Day Range
$214.85
$409.92
52-Week Range
$163.11
$415.00
Dividend Yield
0.89%
IDEXX Laboratories stock logo

34. IDEXX Laboratories NASDAQ:IDXX

$557.80 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$561.50 +3.70 (+0.66%)
As of 07:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. More about IDEXX Laboratories

Pros of IDEXX Laboratories

  • The current stock price is around $534, indicating a strong market position and potential for growth.
  • IDEXX Laboratories, Inc. has a diverse product portfolio, including advanced diagnostic and health-monitoring products for both companion animals and livestock, which can lead to stable revenue streams.
  • The company has shown a positive trend in its fifty-two week performance, suggesting resilience and potential for continued growth in the market.

Cons of IDEXX Laboratories

  • The company has experienced a slight decrease in shares shorted month-to-month, which may indicate some investor skepticism about its short-term performance.
  • With a relatively high days to cover ratio, it may take longer for short sellers to exit their positions, potentially leading to volatility in the stock price.
  • Despite a strong market presence, the competitive landscape in the health care equipment sector is intense, which could impact IDEXX Laboratories, Inc.'s market share.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$44.00 billion
P/E Ratio
41.08
Consensus Rating
Moderate Buy
Consensus Price Target
$751.00 (+34.6% Upside)
Volume
813,547 shares
Average Volume
618,312 shares
Today's Range
$538.87
$559.91
50-Day Range
$526.44
$579.23
52-Week Range
$506.91
$769.98
Dividend Yield
N/A
Becton, Dickinson and Company stock logo

35. Becton, Dickinson and Company NYSE:BDX

$158.10 +0.02 (+0.01%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$157.82 -0.28 (-0.18%)
As of 09:12 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. More about Becton, Dickinson and Company

Pros of Becton, Dickinson and Company

  • The current stock price is around $147.91, which is significantly lower than its 12-month high of $187.35, potentially offering a buying opportunity for investors looking for value.
  • Becton, Dickinson and Company reported a quarterly revenue increase of 5.2% compared to the same quarter last year, indicating strong growth and demand for its medical products.
  • The company has a solid return on equity of 15.37%, suggesting effective management and profitability, which can be attractive to investors seeking reliable returns.

Cons of Becton, Dickinson and Company

  • The company has a high dividend payout ratio of 106.33%, which may raise concerns about sustainability, as it indicates that the company is paying out more in dividends than it is earning.
  • Analysts have mixed ratings on the stock, with a consensus rating of "Hold," suggesting that there may be uncertainty about the stock's future performance.
  • Recent analyst downgrades, including a reduction from a "hold" to a "sell" rating, may indicate potential challenges ahead for the company.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$43.56 billion
P/E Ratio
40.02
Consensus Rating
Hold
Consensus Price Target
$181.00 (+14.5% Upside)
Volume
2.04 million shares
Average Volume
2.71 million shares
Today's Range
$153.93
$158.72
50-Day Range
$140.37
$158.10
52-Week Range
$127.59
$187.35
Dividend Yield
2.66%
Haleon stock logo

36. Haleon NYSE:HLN

$9.80 -0.02 (-0.15%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$9.71 -0.09 (-0.97%)
As of 07/2/2026 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. More about Haleon

Pros of Haleon

  • The current stock price is around $9.08, which may present a buying opportunity for investors looking for value in the consumer healthcare sector.
  • Haleon plc has a diverse product portfolio, including well-known brands in oral health, vitamins, and over-the-counter medications, which can help stabilize revenue streams.
  • The company has a long history, founded in 1715, which may instill confidence in its operational stability and brand recognition in the market.

Cons of Haleon

  • The short percentage of float is relatively low, indicating that there may not be significant bearish sentiment currently, but this could change if market conditions worsen.
  • Institutional ownership is at 0%, which may suggest a lack of confidence from larger investors, potentially impacting stock performance.
  • Recent data shows a month-to-month decrease in shares shorted, which could indicate a lack of momentum or interest from traders looking to capitalize on price movements.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$43.22 billion
P/E Ratio
25.14
Consensus Rating
Moderate Buy
Consensus Price Target
N/A
Volume
9.19 million shares
Average Volume
9.85 million shares
Today's Range
$9.66
$9.82
50-Day Range
$8.71
$9.81
52-Week Range
$8.65
$11.28
Dividend Yield
2.57%
Alnylam Pharmaceuticals stock logo

37. Alnylam Pharmaceuticals NASDAQ:ALNY

$312.78 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$315.53 +2.75 (+0.88%)
As of 09:22 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. More about Alnylam Pharmaceuticals

Pros of Alnylam Pharmaceuticals

  • The company recently reported a significant increase in quarterly revenue, showcasing a year-over-year growth of nearly 100%, indicating strong market demand for its products.
  • Alnylam Pharmaceuticals, Inc. has a high return on equity, suggesting effective management and profitability, which can be attractive to investors looking for efficient use of equity capital.
  • The current stock price is around $463, which is within a range that may present a buying opportunity for investors looking to capitalize on potential future growth.

Cons of Alnylam Pharmaceuticals

  • The stock has a relatively high P/E ratio, which may indicate that it is overvalued compared to its earnings, potentially leading to price corrections.
  • Despite recent revenue growth, the company has previously reported losses, which could raise concerns about its long-term profitability and sustainability.
  • Alnylam Pharmaceuticals, Inc. has a debt-to-equity ratio close to 1, suggesting that it has a significant amount of debt relative to its equity, which could pose risks in a rising interest rate environment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$41.76 billion
P/E Ratio
85.46
Consensus Rating
Moderate Buy
Consensus Price Target
$461.39 (+47.5% Upside)
Volume
1.09 million shares
Average Volume
1.18 million shares
Today's Range
$303.00
$317.17
50-Day Range
$278.09
$313.79
52-Week Range
$273.11
$495.55
Dividend Yield
N/A
Revolution Medicines stock logo

38. Revolution Medicines NASDAQ:RVMD

$189.24 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$192.52 +3.28 (+1.74%)
As of 09:22 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Market Capitalization
$40.23 billion
P/E Ratio
N/A
Consensus Rating
Moderate Buy
Consensus Price Target
$142.33 (-24.8% Downside)
Volume
3.19 million shares
Average Volume
3.18 million shares
Today's Range
$184.29
$189.48
50-Day Range
$131.67
$192.62
52-Week Range
$34.00
$193.10
Dividend Yield
N/A
Natera stock logo

39. Natera NASDAQ:NTRA

$279.32 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$280.37 +1.05 (+0.38%)
As of 09:20 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Market Capitalization
$40.00 billion
P/E Ratio
N/A
Consensus Rating
Moderate Buy
Consensus Price Target
$260.33 (-6.8% Downside)
Volume
1.27 million shares
Average Volume
1.52 million shares
Today's Range
$271.64
$279.63
50-Day Range
$186.36
$279.32
52-Week Range
$131.81
$279.63
Dividend Yield
N/A
Teva Pharmaceutical Industries stock logo

40. Teva Pharmaceutical Industries NYSE:TEVA

$34.55 -0.09 (-0.25%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$35.16 +0.61 (+1.77%)
As of 09:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Market Capitalization
$39.73 billion
P/E Ratio
25.98
Consensus Rating
Moderate Buy
Consensus Price Target
$41.78 (+20.9% Upside)
Volume
4.81 million shares
Average Volume
5.31 million shares
Today's Range
$33.59
$34.92
50-Day Range
$30.66
$36.36
52-Week Range
$14.99
$37.35
Dividend Yield
N/A
Waters stock logo

41. Waters NYSE:WAT

$378.62 -0.67 (-0.18%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$378.35 -0.27 (-0.07%)
As of 09:19 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Further, the company provides thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.

Market Capitalization
$37.18 billion
P/E Ratio
48.11
Consensus Rating
Moderate Buy
Consensus Price Target
$396.68 (+4.8% Upside)
Volume
748,612 shares
Average Volume
890,553 shares
Today's Range
$372.97
$380.00
50-Day Range
$291.73
$384.12
52-Week Range
$275.05
$414.15
Dividend Yield
N/A
Agilent Technologies stock logo

42. Agilent Technologies NYSE:A

$130.79 +0.10 (+0.07%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$129.51 -1.27 (-0.97%)
As of 09:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. More about Agilent Technologies

Pros of Agilent Technologies

  • Agilent Technologies, Inc. has demonstrated strong financial performance, with a return on equity of over 24%, indicating effective management and profitability relative to shareholder equity.
  • The company reported quarterly revenue of approximately $1.83 billion, surpassing analysts' expectations, which reflects robust demand for its scientific instrumentation and services.
  • Agilent Technologies, Inc. has a solid dividend yield of around 0.7%, providing a steady income stream for investors, with a payout ratio of about 20%, suggesting that the company retains a significant portion of its earnings for growth.

Cons of Agilent Technologies

  • Despite strong revenue growth, the company operates in a highly competitive market, which could pressure margins and limit future growth opportunities.
  • The dividend yield, while positive, is relatively low compared to other investment opportunities, which may not attract income-focused investors.
  • Agilent Technologies, Inc. has a significant reliance on the life sciences and diagnostics sectors, making it vulnerable to sector-specific downturns or regulatory changes.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$36.94 billion
P/E Ratio
26.26
Consensus Rating
Moderate Buy
Consensus Price Target
$160.88 (+23.0% Upside)
Volume
2.17 million shares
Average Volume
2.09 million shares
Today's Range
$130.38
$134.48
50-Day Range
$110.43
$138.23
52-Week Range
$108.35
$160.27
Dividend Yield
0.78%
Alcon stock logo

43. Alcon NYSE:ALC

$69.66 0.00 (0.00%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$68.50 -1.16 (-1.67%)
As of 09:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alcon Inc researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. More about Alcon

Pros of Alcon

  • The current stock price is around $87.48, which reflects a stable valuation in the market.
  • Alcon Inc. has shown a month-to-month increase in shares shorted, indicating growing interest from investors, which can be a positive sign for future performance.
  • The company maintains a significant institutional ownership percentage, suggesting confidence from large investors in its long-term prospects.

Cons of Alcon

  • The company has experienced a decline in its fifty-two week performance, which may raise concerns about its growth trajectory and market competitiveness.
  • Despite a recent increase in shares shorted, the overall short interest remains relatively low, which could indicate a lack of strong bullish sentiment among investors.
  • Alcon Inc. has a relatively high number of days to cover, suggesting that it may take longer for short sellers to cover their positions, which can lead to increased volatility in the stock price.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$34.45 billion
P/E Ratio
41.96
Consensus Rating
Moderate Buy
Consensus Price Target
$85.12 (+22.2% Upside)
Volume
1.90 million shares
Average Volume
1.62 million shares
Today's Range
$67.53
$69.75
50-Day Range
$61.98
$76.02
52-Week Range
$61.83
$92.55
Dividend Yield
N/A
IQVIA stock logo

44. IQVIA NYSE:IQV

$206.38 -0.66 (-0.32%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$206.68 +0.31 (+0.15%)
As of 07:57 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. More about IQVIA

Pros of IQVIA

  • The current stock price is around $181, which may be considered attractive compared to its 12-month high of $247.04, indicating potential for growth.
  • Recent quarterly earnings showed a strong performance with earnings per share (EPS) of $2.90, surpassing analysts' expectations, which reflects the company's robust financial health.
  • IQVIA Holdings Inc. has a solid revenue growth of 8.4% compared to the same quarter last year, demonstrating its ability to expand in the competitive life sciences sector.

Cons of IQVIA

  • The company has a relatively high debt-to-equity ratio of 2.20, which may indicate higher financial risk and could affect its ability to manage debt obligations effectively.
  • Despite recent earnings growth, the current ratio and quick ratio are both at 0.75, suggesting potential liquidity issues that could impact short-term financial stability.
  • Some analysts have downgraded their ratings, indicating mixed sentiments in the market, which could lead to volatility in stock performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$34.44 billion
P/E Ratio
25.57
Consensus Rating
Moderate Buy
Consensus Price Target
$222.00 (+7.6% Upside)
Volume
1.20 million shares
Average Volume
1.51 million shares
Today's Range
$203.94
$208.29
50-Day Range
$156.42
$206.38
52-Week Range
$154.50
$247.04
Dividend Yield
N/A
Centene stock logo

45. Centene NYSE:CNC

$67.80 -0.06 (-0.09%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$67.47 -0.32 (-0.47%)
As of 09:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. More about Centene

Pros of Centene

  • Centene Co. recently reported earnings per share (EPS) of $3.37, significantly exceeding analyst expectations, indicating strong financial performance and potential for future growth.
  • The company achieved a revenue of approximately $49.94 billion for the latest quarter, surpassing estimates, which reflects robust demand for its healthcare services.
  • Analysts have a generally positive outlook on Centene Co., with several upgrades to target prices, suggesting confidence in the company's future performance.

Cons of Centene

  • Despite strong revenue growth, Centene Co. has a negative net margin of 3.25%, which may raise concerns about profitability and cost management.
  • The stock has a price-to-earnings (P/E) ratio of -4.82, indicating that the company is currently not profitable based on traditional earnings metrics, which could deter risk-averse investors.
  • There are mixed ratings from analysts, with some issuing "Hold" and "Sell" ratings, suggesting uncertainty about the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$33.48 billion
P/E Ratio
N/A
Consensus Rating
Hold
Consensus Price Target
$60.78 (-10.4% Downside)
Volume
3.86 million shares
Average Volume
5.33 million shares
Today's Range
$67.05
$69.29
50-Day Range
$41.08
$68.34
52-Week Range
$25.08
$69.29
Dividend Yield
N/A
Royalty Pharma stock logo

46. Royalty Pharma NASDAQ:RPRX

$57.77 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$57.98 +0.21 (+0.36%)
As of 09:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. More about Royalty Pharma

Pros of Royalty Pharma

  • The current stock price is around $51, which is near its 50-day moving average, indicating potential stability in the short term.
  • Royalty Pharma plc has demonstrated strong financial performance, with a recent earnings per share (EPS) of $1.30, surpassing analyst expectations, which reflects effective management and profitability.
  • The company boasts a solid return on equity of 29.25%, suggesting that it is efficient in generating profits from its equity investments.

Cons of Royalty Pharma

  • The company reported revenue of $630.58 million, which fell short of analyst expectations, indicating potential challenges in meeting growth targets.
  • Royalty Pharma plc has a price-to-earnings (P/E) ratio of 36.88, which may suggest that the stock is overvalued compared to its earnings, potentially limiting future price appreciation.
  • The debt-to-equity ratio stands at 0.86, indicating a reliance on debt financing, which could pose risks if market conditions change or interest rates rise.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$33.27 billion
P/E Ratio
39.30
Consensus Rating
Buy
Consensus Price Target
$53.71 (-7.0% Downside)
Volume
3.24 million shares
Average Volume
3.30 million shares
Today's Range
$55.62
$57.80
50-Day Range
$49.38
$57.77
52-Week Range
$34.08
$57.80
Dividend Yield
1.63%
BeOne Medicines stock logo

47. BeOne Medicines NASDAQ:ONC

$297.65 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$311.40 +13.75 (+4.62%)
As of 09:20 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Market Capitalization
$32.66 billion
P/E Ratio
66.59
Consensus Rating
Moderate Buy
Consensus Price Target
$390.00 (+31.0% Upside)
Volume
294,918 shares
Average Volume
292,267 shares
Today's Range
$291.87
$300.19
50-Day Range
$260.27
$317.00
52-Week Range
$240.00
$385.22
Dividend Yield
N/A
Biogen stock logo

48. Biogen NASDAQ:BIIB

$216.12 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$215.84 -0.28 (-0.13%)
As of 09:20 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. More about Biogen

Pros of Biogen

  • Biogen Inc. recently reported earnings per share (EPS) of $3.57, significantly exceeding analysts' expectations, which indicates strong financial performance and potential for future growth.
  • The company has set a fiscal year 2026 guidance of EPS between 14.250 and 15.250, suggesting confidence in its future profitability and growth trajectory.
  • Biogen Inc. has a solid return on equity of 12.83%, reflecting effective management and the ability to generate profits from shareholders' investments.

Cons of Biogen

  • Despite recent positive earnings, Biogen Inc.'s revenue growth was only 1.9% compared to the same quarter last year, which may raise concerns about the company's ability to expand significantly.
  • The company has a net margin of 13.81%, which, while positive, may indicate limited profitability compared to competitors in the biotechnology sector.
  • There is a mixed sentiment among analysts, with one rating the stock as a Sell, suggesting that not all market experts are confident in Biogen Inc.'s future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$31.91 billion
P/E Ratio
23.19
Consensus Rating
Moderate Buy
Consensus Price Target
$217.41 (+0.6% Upside)
Volume
1.15 million shares
Average Volume
1.10 million shares
Today's Range
$210.75
$219.02
50-Day Range
$180.67
$216.63
52-Week Range
$121.05
$219.72
Dividend Yield
N/A
Moderna stock logo

49. Moderna NASDAQ:MRNA

$79.76 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$78.54 -1.23 (-1.54%)
As of 09:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. More about Moderna

Pros of Moderna

  • The company has recently reported a significant increase in quarterly revenue, showcasing a growth of over 260% compared to the same quarter last year, indicating strong demand for its products.
  • Moderna, Inc. specializes in messenger RNA (mRNA) therapeutics and vaccines, a cutting-edge technology that has gained prominence, particularly with its COVID-19 vaccine, which has received full approval in multiple jurisdictions.
  • The current stock price is around $36.60, which reflects a consensus rating of "Reduce" from analysts, suggesting potential for value buying if the company can turn around its financial performance.

Cons of Moderna

  • The company has reported a negative return on equity of over 26%, indicating that it is currently not generating profit relative to shareholder equity, which can be a red flag for potential investors.
  • Moderna, Inc. has a negative net margin of approximately 143.55%, suggesting that the company is not only unprofitable but also losing money on its sales, which raises concerns about its financial health.
  • Analysts expect the company to post an earnings per share (EPS) of -6.51 for the current fiscal year, indicating ongoing challenges in achieving profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$31.65 billion
P/E Ratio
N/A
Consensus Rating
Reduce
Consensus Price Target
$37.13 (-53.4% Downside)
Volume
14.01 million shares
Average Volume
8.59 million shares
Today's Range
$73.68
$81.40
50-Day Range
$45.64
$79.76
52-Week Range
$22.28
$81.40
Dividend Yield
N/A
Zoetis stock logo

50. Zoetis NYSE:ZTS

$74.74 -0.07 (-0.09%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$75.12 +0.39 (+0.52%)
As of 09:22 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. More about Zoetis

Pros of Zoetis

  • Zoetis Inc. has demonstrated strong financial performance with a high return on equity, indicating effective management and profitability.
  • The company has a solid net margin, suggesting that it retains a significant portion of revenue as profit, which can be beneficial for shareholders.
  • Recent revenue growth of nearly 3% compared to the previous year shows resilience and potential for continued expansion in the animal health market.

Cons of Zoetis

  • The dividend payout ratio is relatively high, which could limit the company's ability to reinvest profits back into growth initiatives.
  • While revenue is growing, the rate of growth is modest, which may not meet the expectations of more aggressive investors.
  • Market conditions in the animal health sector can be unpredictable, potentially impacting future performance and stock stability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$31.33 billion
P/E Ratio
12.39
Consensus Rating
Hold
Consensus Price Target
$126.92 (+69.8% Upside)
Volume
4.35 million shares
Average Volume
6.63 million shares
Today's Range
$72.90
$75.05
50-Day Range
$71.88
$117.85
52-Week Range
$71.47
$161.77
Dividend Yield
2.83%